Cited by 318Pharmaceutical studies and practicesStatistical Methods in Clinical TrialsPharmaceutical Economics and Policy

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs

Dunne, Julia, Rodriguez, William J., Murphy, M. Dianne, Beasley, B. Nhi, Burckart, Gilbert J., Filie, Jane D., Lewis, Linda L., Sachs, Hari C., Sheridan, Philip H., Starke, Peter, Yao, Lynne P.·2011·Pediatrics

DOI 10.1542/peds.2010-3487

Open this paper in CoChat — free account

Abstract

OBJECTIVES: In 1994, the US Food and Drug Administration (FDA) proposed an approach, based on extrapolation of efficacy findings from adults to the pediatric population, to maximize the use of adult data and other data when designing pediatric drug-development programs. We examined the experience of the FDA in using extrapolation to evaluate how and when it was used and any changes in scientific assumptions over time. METHODS: We reviewed 370 pediatric studies submitted to the FDA between 1998 and 2008 in response to 159 written requests (166 products) issued under the Pediatric Exclusivity Provision. We identified cases in which efficacy was extrapolated from adult data or other data, we categorized the type of pediatric data required to support extrapolation, and we determined whether the data resulted in new pediatric labeling. RESULTS: Extrapolation of efficacy from adult data occurred for 82.5% of the drug products (137 of 166). Extrapolation was defined as complete for 14.5% of the products (24 of 166) and partial for 68% of them (113 of 166). Approaches to extrapolation changed over time for 19% of the therapeutic indications studied (13 of 67). When extrapolation was used, 61% of the drug products (84 of 137) obtained a new pediatric indication or extension into a new age group; this number decreased to 34% (10 of 29) when there was no extrapolation. CONCLUSIONS: Extrapolating efficacy from adult data or other data to the pediatric population can streamline pediatric drug development and help to increase the number of approvals for pediatric use.

Integrity signals

Registry

Crossref · 10.1542/peds.2010-3487

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,913
Carvedilol for Children and Adolescents With Heart Failure
Shaddy, R. E., Boucek, M. M., Hsu, D. T., Boucek, R. J., Canter, C. E., Mahony, L., Ross, R. D., Pahl, E., Blume, E. D., Dodd, D. A., et al. (2007) · JAMA · doi:10.1001/jama.298.10.1171 · Cited by 571
Therapeutic orphans.
Shirkey, H. C. (1968) · PubMed · doi:10.1016/s0022-3476(68)80414-7 · Cited by 363
An Update on the Therapeutic Orphan
Wilson, J. T. (1999) · PEDIATRICS · doi:10.1542/peds.104.s3.585 · Cited by 172
Pediatric Antihypertensive Trial Failures
Benjamin, D. K., Smith, P. B., Jadhav, P. R., Gobburu, J. V. S., Murphy, M. D., Hasselblad, V., Baker-Smith, C. M., Califf, R. M., & Li, J. S. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108886 · Cited by 123
Self-citation
Food and Drug Administration Modernization Act
Tsien, A., & Pahl, P. (2004) · CRC Press eBooks · doi:10.1201/9780203997048-9 · Cited by 120
Juvenile Idiopathic Arthritis
Weiss, J. E., & Ilowite, N. T. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.07.006 · Cited by 104
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure
Albers, S., Meibohm, B., Mir, T. S., & Läer, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03046.x · Cited by 68
The pediatric randomized carvedilol trial in children with chronic heart failure: Rationale and design
Shaddy, R. E., Curtin, E., Sower, B., Tani, L. Y., Burr, J. S., LaSalle, B. A., Boucek, M. M., Mahony, L., Hsu, D. T., Pahl, E., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124402 · Cited by 54
Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease
Nishiyama, M., Park, I., Yoshikawa, T., Hatai, Y., Ando, M., Takahashi, Y., Mori, K., & Murakami, Y. (2009) · Heart and Vessels · doi:10.1007/s00380-008-1102-5 · Cited by 30

Show all 10 references

Research works printed but not linked: 1

Food and Drug Administration, 1994, Specific requirements on content and format of labeling for human prescription drugs: revision of “pediatric use” subsection in the labeling: final rule, Fed Regist, 59

Sorted by citations

Standard 6: Age Groups for Pediatric Trials
Williams, K. J., Thomson, D., Seto, I., Contopoulos‐Ioannidis, D. G., Ioannidis, J. P. A., Curtis, S. J., Constantin, E., Batmanabane, G., Hartling, L., & Klassen, T. P. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0055i · Cited by 555
Pediatric Drug Formulations: A Review of Challenges and Progress
Ivanovska, V., Rademaker, C. M. A., van Dijk, L., & Mantel-Teeuwisse, A. K. (2014) · PEDIATRICS · doi:10.1542/peds.2013-3225 · Cited by 328
Paediatric drug development: The impact of evolving regulations
Turner, M. A., Catapano, M., Hirschfeld, S., & Giaquinto, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.003 · Cited by 167
Paediatric oral biopharmaceutics: Key considerations and current challenges
Batchelor, H. K., Fotaki, N., & Klein, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.006 · Cited by 141
Management of thrombosis in children and neonates: practical use of anticoagulants in children
Monagle, P., & Newall, F. H. (2018) · Hematology · doi:10.1182/asheducation-2018.1.399 · Cited by 133
Beyond Randomized Clinical Trials: Use of External Controls
Schmidli, H., Häring, D. A., Thomas, M., Cassidy, A., Weber, S., & Bretz, F. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1723 · Cited by 125
Pharmacological interventions for chronic pain in children: an overview of systematic reviews
Eccleston, C., Fisher, E., Cooper, T. E., Grégoire, M.-C., Heathcote, L. C., Krane, E. J., Lord, S. M., Sethna, N. F., Anderson, A.-K., Anderson, B. J., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001609 · Cited by 111
Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates
Ward, R. M., Benjamin, D. K., Barrett, J. S., Allegaert, K., Portman, R. J., Davis, J. M., & Turner, M. A. (2016) · Pediatric Research · doi:10.1038/pr.2016.221 · Cited by 107
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 109
White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens
Infectious Diseases Society of America (IDSA) (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis688 · Cited by 101
Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children
Vinks, A. A. T. M. M., Emoto, C., & Fukuda, T. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.169 · Cited by 99
A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants
Beam, K., Aliaga, S. R., Ahlfeld, S. K., Cohen‐Wolkowiez, M., Smith, P. B., & Laughon, M. M. (2014) · Journal of Perinatology · doi:10.1038/jp.2014.126 · Cited by 98
Failed Pediatric Drug Development Trials
Momper, J. D., Mulugeta, Y. A., & Burckart, G. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.142 · Cited by 94
Self-citation
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
Burt, T., Yoshida, K. J., Lappin, G., Vuong, L. T., John, C. S., de Wildt, S. N., Sugiyama, Y., & Rowland, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12390 · Cited by 96
Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation
Gamalo, M., Savić, J., Basu, C., Zhao, X., Gopalakrishnan, M., Gao, A., Song, G., Baygani, S., Thompson, L., Xia, H. A., et al. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1807 · Cited by 89
Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy
Wharton, G. T., Murphy, M. D., Avant, D., Goldsmith, J. V., Chai, G., Rodriguez, W. J., & Eisenstein, E. L. (2014) · Pediatrics · doi:10.1542/peds.2013-2987 · Cited by 90
Self-citation
Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future
O’Hara, K. E., Wright, I. M. R., Schneider, J. J., Jones, A. L., & Martin, J. H. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12741 · Cited by 89
Pharmacokinetic studies in children: recommendations for practice and research
Barker, C. I. S., Standing, J. F., Kelly, L. E., Faught, L., Needham, A. C., Rieder, M. J., de Wildt, S. N., & Offringa, M. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-314506 · Cited by 84
Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis
Adedokun, O. J., Xu, Z., Padgett, L., BLANK, M. A., Johanns, J., Griffiths, A. M., Ford, J. A., Zhou, H., Guzzo, C. A., Davis, H. M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000435438.84365.f7 · Cited by 84
A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study
Payne, R. M., Burns, K. M., Glatz, A. C., Li, D., Li, X., Monagle, P., Newburger, J. W., Swan, E. A., Wheaton, O. A., & Male, C. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.002 · Cited by 81
The Need for Pediatric Drug Development
Ward, R. M., Benjamin, D. K., Davis, J. M., Gorman, R. L., Kauffman, R. E., Kearns, G. L., Murphy, M. D., & Sherwin, C. M. T. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.08.011 · Cited by 83
Self-citation
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Germovsek, E., Barker, C. I. S., Sharland, M., & Standing, J. F. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0659-0 · Cited by 89
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
Monagle, P., Lensing, A. W. A., Thelen, K., Martinelli, I., Male, C., Santamaría, A., Samochatova, E. V., Kumar, R., Holzhauer, S., Saracco, P., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30161-9 · Cited by 79
Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development
Mulugeta, Y. A., Barrett, J. S., Nelson, R. M., Eshete, A. T., Mushtaq, A., Yao, L. P., Glasgow, N., Mulberg, A. E., González, D., Green, D. J., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.744 · Cited by 78
Self-citation
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
Nachman, S., Ahmed, A. I., Amanullah, F., Becerra, M. C., Botgros, R., Brigden, G., Browning, R., Gardiner, E., Hafner, R., Hesseling, A. C., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00007-9 · Cited by 77
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
Mulberg, A. E., Bucci-Rechtweg, C. M., Giuliano, J. D., Jacoby, D. R., Johnson, F. K., Liu, Q., Marsden, D., McGoohan, S., Nelson, R. M., Patel, N., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1017-5 · Cited by 71
Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned
Sun, H., Temeck, J. W., Chambers, W., Perkins, G., Bonnel, R., & Murphy, D. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017725558 · Cited by 70
The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop
Manolis, E., Rohou, S., Hemmings, R., Salmonson, T., Karlsson, M., & Milligan, P. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.7 · Cited by 70
Pediatric clinical trials
Bavdekar, S. B. (2013) · Perspectives in Clinical Research · doi:10.4103/2229-3485.106403 · Cited by 68
Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: The case for disease similarity
Pellock, J. M., Arzimanoglou, A. A., D’Cruz, O., Holmes, G. L., Nordli, D. R., & Shinnar, S. (2017) · Epilepsia · doi:10.1111/epi.13859 · Cited by 67
Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework
van der Zanden, T. M., Mooij, M. G., Vet, N. J., Neubert, A. C., Rascher, W., Lagler, F. B., Male, C., Grytli, H. H., Halvorsen, T., de Hoog, M., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2336 · Cited by 66
Rational development and utilization of antibody-based therapeutic proteins in pediatrics
Xu, Z., Davis, H. M., & Zhou, H. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.005 · Cited by 63
Off‐Label, but on‐Evidence? A Review of the Level of Evidence for Pediatric Pharmacotherapy
van der Zanden, T. M., Smeets, N. J. L., de Hoop‐Sommen, M. A., Schwerzel, M. F. T., Huang, H. J., Barten, L. J. C., van der Heijden, J. E. M., Freriksen, J. J. M., Horstink, A. A. L., Holsappel, I., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2736 · Cited by 58
Reference Values for 30 Common Biochemistry Analytes Across 5 Different Analyzers in Neonates and Children 30 Days to 18 Years of Age
Hoq, M., Matthews, S. J., Karlaftis, V., Burgess, J., Cowley, J., Donath, S. M., Carlin, J. B., Yen, T., Ignjatović, V., & Monagle, P. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.306431 · Cited by 57
Pharmacogenomic testing in paediatrics: Clinical implementation strategies
Barker, C. I. S., Groeneweg, G. S. S., der Zee, A. H. M., Rieder, M. J., Hawcutt, D. B., Hubbard, T., Swen, J. J., & Carleton, B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15181 · Cited by 55
Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary
Turner, D., Griffiths, A. M., Wilson, D. C., Mould, D. R., Baldassano, R. N., Russell, R. K., Dubinsky, M. C., Heyman, M. B., de Ridder, L., Hyams, J. S., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317987 · Cited by 55
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling
Badée, J., Fowler, S., de Wildt, S. N., Collier, A., Schmidt, S., & Parrott, N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0681-2 · Cited by 43
Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis
Denti, P., Garcia‐Prats, A. J., Draper, H. R., Wiesner, L., Winckler, J. L., Thee, S. A., Dooley, K. E., Savić, R. M., McIlleron, H., Schaaf, H. S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01521-17 · Cited by 51
Anesthetic use in newborn infants: the urgent need for rigorous evaluation
Nasr, V. G., & Davis, J. M. (2015) · Pediatric Research · doi:10.1038/pr.2015.58 · Cited by 50
Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct
Turner, M. A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12467 · Cited by 52
Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods
Wadsworth, I., Hampson, L. V., & Jaki, T. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280216631359 · Cited by 49
Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta‐analysis
Rosati, A., Ilvento, L., Lucenteforte, E., Pugi, A., Crescioli, G., McGreevy, K. S., Virgili, G., Mugelli, A., MASI, S. D., & Guerrini, R. (2017) · Epilepsia · doi:10.1111/epi.13981 · Cited by 49
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
Gupta, A., Hughes, M. D., Garcia‐Prats, A. J., McIntire, K. N., & Hesseling, A. C. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002882 · Cited by 50
A Review of the New Antiepileptic Drugs for Focal-Onset Seizures in Pediatrics: Role of Extrapolation
Arzimanoglou, A. A., D’Cruz, O., Nordli, D. R., Shinnar, S., & Holmes, G. L. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0286-0 · Cited by 44
Commentary on the EMA R eflection P aper on the use of extrapolation in the development of medicines for paediatrics
Ollivier, C., Thomson, A., Manolis, E., Blake, K. V., Karlsson, K. E., Knibbe, C. A. J., Pons, G., & Hemmings, R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13883 · Cited by 42
From clinical trials of antiepileptic drugs to treatment
Perucca, E. (2018) · Epilepsia Open · doi:10.1002/epi4.12239 · Cited by 41
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
Lensing, A. W. A., Male, C., Young, G. A., Kubitza, D., Kenet, G., Massicotte, M. P., Chan, A. K. C., Molinari, A. C., Nowak-Goettl, U., Pap, A. F., et al. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0188-y · Cited by 41
Drug Studies in Newborns: A Therapeutic Imperative
Giacoia, G. P., Taylor‐Zapata, P., & Zajicek, A. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.016 · Cited by 40
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Waalewijn, H., Chan, M. K., Bollen, P., Mujuru, H. A., Makumbi, S., Kekitiinwa, A., Kaudha, E., Sarfati, T., Musoro, G., Nanduudu, A., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(21)00292-7 · Cited by 40
Model averaging for robust extrapolation in evidence synthesis
Röver, C., Wandel, S., & Friede, T. (2018) · Statistics in Medicine · doi:10.1002/sim.7991 · Cited by 40
Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation
Barrett, J. S., Bishai, R., Bucci‐Rechtweg, C., Cheung, A., Corriol‐Rohou, S., Haertter, S., James, A., Kovacs, S. J., Liu, J., Potempa, D., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1000 · Cited by 38
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review
Guimarães, M., Statelova, M., Holm, R., Reppas, C. I., Symillides, M., Vertzoni, M., & Fotaki, N. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12955 · Cited by 37
A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development
Wang, J., Avant, D. A., Green, D., Seo, S. K., Fisher, J., Mulberg, A. A., McCune, S., & Burckart, G. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.149 · Cited by 35
Self-citation
Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates
Hornik, C. P. V., Benjamin, D. K., Smith, P. B., Pencina, M. J., Tremoulet, A. H., Capparelli, E. V., Ericson, J. E., Clark, R. H., & Cohen‐Wolkowiez, M. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.07.011 · Cited by 35
Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children
Balevic, S. J., & Cohen‐Wolkowiez, M. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1053 · Cited by 38
Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens
Stockmann, C. R., Barrett, J. S., Roberts, J., & Sherwin, C. M. T. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12038 · Cited by 34
A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically‐Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate
Wu, Q., & Peters, S. A. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12385 · Cited by 35
Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development
Momper, J. D., & Wagner, J. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.227 · Cited by 32
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older
Franzese, R. C., McFadyen, L., Watson, K. J., Riccobene, T. A., Carrothers, T. J., Vourvahis, M., Chan, P. L. S., Raber, S. R., Bradley, J. S., & Lovern, M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2460 · Cited by 32
Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing
Natale, S., Bradley, J. S., Nguyen, W. H., Tran, T. M., Ny, P., La, K. P., Vivian, E., & Lê, J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1899 · Cited by 32
Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population
Freriksen, J. J. M., van der Heijden, J. E. M., de Hoop‐Sommen, M. A., Greupink, R., & de Wildt, S. N. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00535-w · Cited by 31
Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
Svensson, E. M., Yngman, G., Denti, P., McIlleron, H., Kjellsson, M. C., & Karlsson, M. O. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0577-6 · Cited by 31
Joining Forces: A Call for Greater Collaboration to Study New Medicines in Children and Adolescents With Type 2 Diabetes
Karres, J., Pratt, V., Guettier, J., Temeck, J. W., Tamborlane, W. V., Dunger, D. B., Bejnariu, C., de Beaufort, C. E., & Tomasi, P. A. (2014) · Diabetes Care · doi:10.2337/dc14-0494 · Cited by 30
Pediatric melanoma—The whole (conflicts of interest) story
Rose, K., & Grant-Kels, J. M. (2018) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2018.10.020 · Cited by 30
The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More
Burckart, G. J., & Kim, C. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.7.565 · Cited by 30
Self-citation
Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.
Breton, J., Kastl, A., Conrad, M. A., & Baldassano, R. N. (2020) · PubMed Central · Cited by 30
Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
Bai, J. P. F., Barrett, J. S., Burckart, G. J., Meibohm, B., Sachs, H. C., & Yao, L. P. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9452-z · Cited by 30
Self-citation
Evidence, eminence and extrapolation
Hlavin, G., König, F., Male, C., Posch, M., & Bauer, P. (2016) · Statistics in Medicine · doi:10.1002/sim.6865 · Cited by 30
Development of Drug Therapies for Newborns and Children
Mulugeta, Y. A., Zajicek, A., Barrett, J., Sachs, H. C., McCune, S., Sinha, V. P., & Yao, L. P. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.08.015 · Cited by 29
Self-citation
The Meanings of “Pediatric Drug Development”
Rose, K., & Grant-Kels, J. M. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479018812060 · Cited by 28
Developmental Pharmacodynamics and Modeling in Pediatric Drug Development
Conklin, L. S., Hoffman, E. P., & van den Anker, J. N. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1482 · Cited by 27
Paediatric oral formulations: Why don't our kids have the medicines they need?
Juárez‐Hernández, J. E., & Carleton, B. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15456 · Cited by 27
Global shortage of neonatal and paediatric antibiotic trials: rapid review
Thompson, G., Barker, C. I. S., Folgori, L., Bielicki, J. A., Bradley, J. S., Lutsar, I., & Sharland, M. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016293 · Cited by 27
Rational Use of Medicine in Children—The Conflict of Interests Story. A Review
Rose, K., Neubauer, D., & Grant-Kels, J. M. (2019) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10371 · Cited by 27
Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children’s Pediatric Innovation Research Forum
Noel, G. J., Nelson, R. M., Bucci-Rechtweg, C. M., Portman, R. J., Miller, T., Green, D. J., Snyder, D. L., Moreno, C., Hovinga, C. A., & Connor, E. M. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00283-y · Cited by 26
Pharmacogenomic information in FDA‐approved drug labels: Application to pediatric patients
Green, D., Mummaneni, P., Iw, K., Oh, J., Pacanowski, M. A., & Burckart, G. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.330 · Cited by 26
Self-citation
How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians
Vermeulen, E., van den Anker, J. N., Pasqua, O. E. D., Hoppu, K., & van der Lee, J. H. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12637 · Cited by 26
Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update
Galanopoulou, A. S., Mowrey, W. B., Liu, W., Li, Q., Shandra, O. O., & Moshé, S. L. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2282-0 · Cited by 26
Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
Willmann, S., Frei, M., Sutter, G., Coboeken, K., Wendl, T., Eißing, T., Lippert, J., & Staß, H. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12446 · Cited by 25
Pediatric Efficacy Extrapolation in Drug Development Submitted to the US Food and Drug Administration 2015–2020
Samuels, S., Park, K., Bhatt‐Mehta, V., Sun, H., Mulugeta, Y. A., Yao, L. P., Green, D. J., & Burckart, G. J. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2160 · Cited by 25
Self-citation
Useful pharmacodynamic endpoints in children: selection, measurement, and next steps
Kelly, L. E., Sinha, Y., Barker, C. I. S., Standing, J. F., & Offringa, M. (2018) · Pediatric Research · doi:10.1038/pr.2018.38 · Cited by 25
Use of Real‐World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age
Lukka, P. B., Woods, M., Chhim, R. F., Phelps, S. J., Wheless, J. W., & Meibohm, B. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1840 · Cited by 23
Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions
Auvin, S., Avberšek, A., Bast, T., Chiron, C., Guerrini, R., Kaminski, R. M., Lagae, L. G., Muglia, P., & Cross, J. H. (2019) · Drugs · doi:10.1007/s40265-019-01223-9 · Cited by 23
Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period
Samardžić, J., Allegaert, K., Wilbaux, M., Pfister, M., & van den Anker, J. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1147559 · Cited by 22
Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation
Wadsworth, I., Jaki, T., Sills, G. J., Appleton, R. E., Cross, J. H., Marson, A. G., Martland, T., McLellan, A. E., Smith, P. E. M., Pellock, J. M., et al. (2016) · CNS Drugs · doi:10.1007/s40263-016-0383-y · Cited by 22
Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children
Schaaf, H. S., Garcia‐Prats, A. J., McKenna, L., & Seddon, J. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1421067 · Cited by 22
Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012‐2020
Green, F. G., Park, K., & Burckart, G. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1853 · Cited by 22
Self-citation
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies
Jacobs, T. G., Schouwenburg, S., Penazzato, M., Archary, M., Ruel, T., van den Anker, J. N., Burger, D. M., Cressey, T. R., Abrams, E. J., Lyall, H., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00121-7 · Cited by 22
Self-citation
Extrapolation as a Default Strategy in Pediatric Drug Development
Gamalo, M., Bucci-Rechtweg, C. M., Nelson, R. M., Vanh, L., Porcalla, A., Thackray, H. M., Cooner, F., Cutler, L., Friend, D., & Portman, R. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00367-9 · Cited by 22
Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model.
Cristofoletti, R., Charoo, N. A., & Dressman, J. (2016) · Journal of Pharmacy and Science · doi:10.1016/j.xphs.2016.01.027 · Cited by 21
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry
Siegfried, E. C., Jaworski, J. C., Eichenfield, L. F., Paller, A. S., Hebert, A. A., Simpson, E. L., Altman, E., Arena, C., Blauvelt, A., Block, J. K., et al. (2018) · Pediatric Dermatology · doi:10.1111/pde.13452 · Cited by 20
Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
Sun, K., Hayes, S. C., Farrell, C. B., & Song, I. H. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12943 · Cited by 19
Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review
Folgori, L., Bielicki, J. A., Ruiz, B., Turner, M. A., Bradley, J. S., Benjamin, D. K., Zaoutis, T. E., Lutsar, I., Giaquinto, C., Rossi, P., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00069-4 · Cited by 19
Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go
van Dijkman, S. C., Álvarez-Jiménez, R., Danhof, M., & Pasqua, O. E. D. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1203900 · Cited by 19
Surfactant Administration in Preterm Infants: Drug Development Opportunities
Taylor, G., Jackson, W., Hornik, C. P. V., Koss, A. R., Mantena, S., Homsley, K., Gattis, B., Kudumu-Clavell, M., Clark, R. H., Smith, P. B., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.11.041 · Cited by 19
Exposure–Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration
Zhang, Y., Wang, Y., Khurana, M., Sachs, H. C., Zhu, H., Burckart, G. J., Alexander, J., Yao, L. P., & Wang, J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1809 · Cited by 19
Self-citation
Phase 0, including microdosing approaches: applying the three Rs and increasing the efficiency of human drug development
Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R. (2018) · Alternatives to Laboratory Animals · doi:10.1177/026119291804600603 · Cited by 18
Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study
Liu, P., Ioannidis, J. P. A., Ross, J. S., Dhruva, S. S., Luxkaranayagam, A. T., Vasiliou, V., & Wallach, J. D. (2019) · BMC Medicine · doi:10.1186/s12916-019-1420-8 · Cited by 19
Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder
Kalaria, S. N., Farchione, T. R., Uppoor, R. S., Mehta, M., Wang, Y., & Zhu, H. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1836 · Cited by 18
Bridging studies in support of oral pediatric formulation development
Ricci, B. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.074 · Cited by 18

Authors: Dunne, J., Rodriguez, W. J., Murphy, M. D., Beasley, B. N., Burckart, G. J., Filie, J. D., Lewis, L. L., Sachs, H. C., Sheridan, P. H., Starke, P., & Yao, L. P.
Affiliations: Office of Pediatric Therapeutics, Office of the Commissioner,
Divisions of Cardiorenal Products,
United States Food and Drug Administration (US)
Anesthesia, Analgesia, and Rheumatology Products,
Sarepta Therapeutics (United States) (US)
Pediatric and Maternal Health Staff,
Neurology Products,
Pulmonary and Allergy Associates (US)
Gastroenterology Products, and
Corresponding author: Dunne, Julia
ORCID: Murphy, M. Dianne
Burckart, Gilbert J.
Lewis, Linda L.
Yao, Lynne P.
Venue: Pediatrics
Publisher: American Academy of Pediatrics (AAP)
Published: 2011-11-01
Volume: 128
Issue: 5
Pages: e1242-e1249
ISSN: 0031-4005 (ISSN-L)
1098-4275
DOI: 10.1542/peds.2010-3487
OpenAlex: W2123246083
Cited by: 318
References: 10
Citations by year: 2026: 7 · 2025: 14 · 2024: 20 · 2023: 16 · 2022: 30 · 2021: 26 · 2020: 27 · 2019: 36 · 2018: 31 · 2017: 30 · 2016: 25 · 2015: 22 · 2014: 14 · 2013: 15 · 2012: 5
FWCI: 10.04
Type: journal article
Language: en
Open access: closed
Locations: PEDIATRICS (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: pediatric drug development, FDA regulatory policy
MeSH terms: Adult, Age Factors, Child, Child, Preschool, Data Interpretation, Statistical, Drug Therapy, Pharmaceutical Preparations, Female, Humans, Infant, Male, Pediatrics, Quality Control, Retrospective Studies, United States, United States Food and Drug Administration, Drug Design, Cohort Studies, Program Development, Drug Dosage Calculations, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks